Introduction
A serious effort has been made to come to an international consensus about the definition, sub classification of ISS, diagnosis and treatment. [1] The definition of ISS is based on the exclusion of other likely causes of short stature, as well as on the following minimal criteria: height less than third percentile or more than 2 SD below mean for age and sex, growth velocity below 10 th centile or less, bone age two or more years behind chronological age, normal findings from provocation GH tests (peak > 10 ng/ml) with no evidence of chronic organic disease nor psychological or severe emotional disturbance. [2] It is estimated that approximately 60-80% of all short children at or below -2 SDS fit the definition of ISS. [3] Multiple factors affect the growth response to GH, many of which are unknown. [1] Our aim is to evaluate the growth responses of children with ISS treated with rhGH, aiming to identify the predictors of growth response.
Materials and Methods

Patients
All patients were referred from different schools all over Egypt to the GH National Committee of the school health insurance, where they were diagnosed, provided by growth hormone and followed in association with the growth unit of the Diabetes Endocrine Metabolism Pediatric Unit (DEMPU), Children Hospital, Cairo University.
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All patients had the inclusion criteria of a stature more than 2 SDS below the mean, growth velocity below the tenth centile for age and sex and a normal GH peak value (more than10 ng/ml) in at least one of the provocation tests. Children with dysmorphic phenotypes, such as skeletal dysplasias or Turner syndrome, and those with birth weight or length that are small for gestational age should be excluded from the ISS diagnostic category as are children with clearly identified causes of short stature (e.g. celiac disease, inflammatory bowel disease, juvenile chronic arthritis, GHD or GH resistance, hypothyroidism, Cushing's syndrome, etc.). They were 120 cases, 90 cases were males (75%), with a mean age of 13.8±2.7
years and 30 cases were females (25%), with a mean age of 12.3±2.5 years.
Methods
Informed consent was taken from the parents of children; then all cases were subjected to the following.
Full history taking and clinical examinations were done.
Full anthropometric assessment was also done, including target and mid-parental heights. Target height was calculated by the method of Tanner et al, taking the average of mother's and father's height after addition of 13 cm in boys or subtractions of them in girls, while mid-parental height is calculated as before ± 6.5 cm. [4] Height was measured twice and neared to the next IGF-1 (IRMA) was included in a sample extraction step in which IGF-1 was separated from its binding protein in serum. This step is considered to be essential for accurate determination of IGF1. [7, 8] 
Results
Descriptive statistic is presented in Table 1 Table 5 ], there was a significant difference between IGF-1 SDS in the 1 st year compared to 3 rd year (P-value = 0.008) and between IGFBP-3 SDS in the 1 st year and the 3 rd and 4 th years (P-value = 0.001).
Discussion
In children with ISS, short-term outcome measures (<2 years) must take into account the age, pubertal status, and degree of growth retardation of the individual patient. The change in height SDS will provide the best indicator of response, but height velocity, height velocity SDS, and the change in height velocity(cm per year or SDS) all have utility, and are sometimes superior, in assessing response. [1] Long-term auxological parameters that define the success of therapy include adult height SDS, adult height SDS minus height SDS at start of GH, adult height minus predicted height, and adult height minus target height. [1] In the present study, we included a cohort of 120 patients with idiopathic short stature. Our GH dose is in accordance with that used by in cases of ISS. [9] On GH therapy, patients showed catch up growth during 1 st and 2 nd years followed by a plateau response. childhood is an important consideration. [10] For 92 subjects who completed GH therapy for three years in Hopwood's study [11] the GV increased from 4.6
cm/year before treatment to a mean of 8. There has been much disagreement concerning the prognosis of adult height in children with ISS. This may be related to the lack of precise classification where some children seem to have a combination of genetic short stature and constitutional delay, while others seem to have a growth disorder based on their pathologic growth rate and height. Until there is a wide availability of genetic tests for mutation in the genes for GH and GH receptors, treatment decision will depend on a clinical judgment. [12] In our patients with ISS, the mean age for spontaneous pubertal maturation was 11.9±1.1 years for girls and 12.6±1.9 years for boys. This to be compared with the mean age reported by Reckers et al, (11.4±0.9 years for girls, 13.1±1.4 years for boys) and Ranke and Lindberg, (12 years for girls and 12.6 years for boys). [13, 14] In the present work, we tried to identify factors that may predict the growth response to GH treatment in this group of short children by applying a multiple linear regression analysis. [15, 16] Baseline and treatment-related IGF-I has not been validated in long-term studies, but two-year studies suggest that the rise in IGF-I correlates with short-term height gain. [17] IGF-I levels may be helpful in assessing compliance and GH sensitivity; levels that are consistently elevated (>2.5 SDS) should prompt consideration of GH dose reduction. [1] For the third year, the growth response was positively In a longitudinal study of ISS subjects, bone age delay had an impact on the accuracy of prediction. In children with a bone age delay around two year, the average adult height was close to the predicted height, and in those with no bone age delay, adult height surpassed the initial prediction substantially, although if the bone age was delayed by more than two year, adult height was considerably below predicted height. [16] In our patients with idiopathic short stature, only one The mean increase in adult height attributable to GH therapy (average duration of 4-7 year) in children with ISS is 3.5-7.5 cm compared with historical controls, [18, 19] with patients' own pretreatment predicted adult heights, [20] or with no treatment control or placebo control groups. [17, 21] Responses are highly variable and are dose dependent.
Concern has been raised that higher GH doses (>53 µg/kg/d) may advance the bone age and the onset of puberty. [22] The reason for the marked discrepancy between Ismail et al.: Growth response of children with idiopathic short stature these data and the majority of the previously mentioned reports is the possibility of initiation of GH treatment at younger age.
It is apparent from our previous data that the multiplicity of predictors that is responsible for response variability in patients with ISS treated with GH, are lacking a characteristic pattern either in the period of catch up growth or in the period of stable growth. This confirms the complexity of growth response in ISS patients, with multidimensional parameters from different categories.
